PROCEPT BioRobotics Corporation
HealthcareNASDAQ:PRCT · NASDAQ Global Market
-$1.99 today
Vol 1.38M · Avg 1.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-26.1%
avg -54.8%
ROIC
-23.5%
avg -34.2%
ROA
-18.8%
avg -31.1%
Analysis
ROA is currently the strongest return metric at -18.8% versus its period average of -31.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Larry L. Wood | President, Chief Executive Officer & Director | $2.34M | — | 60 | $313,378.00 | 0.55% |
Kevin Waters | Executive Vice President & Chief Financial Officer | $765,898.00 | — | 49 | $151,201.00 | 0.27% |
Alaleh Nouri | EVice President, Chief Legal Officer & Corporate Secretary | $699,426.00 | — | 47 | $105,069.00 | 0.18% |
Pooja Sharma Rao | Executive VP and Chief Strategy & Marketing Officer | — | — | — | $87,559.00 | 0.15% |
Stacey L. Porter | Executive VP & Chief People Officer | — | — | 51 | — | — |
Barry Templin | Executive Vice President & Chief Technology Officer | — | — | — | $68,953.00 | 0.12% |
Bijesh Chandran | Executive Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — | — |
Christofer Christoforou | Executive Vice President of Operations | — | — | 56 | — | — |
Stephen J. McGill | Senior VP & GM of International | — | — | 64 | — | — |
Matthew James Bacso | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$11.27M
Sells
11
$601,995.73
Net Sentiment
+$10.67M
Net buying
Most Active
Nouri Alaleh
7 transactions
1–10 of 19
Analysis
Insiders reported 8 buys worth $11.27M and 11 sells worth $601,995.73 over the last 12 months. That adds up to net buying of $10.67M. Nouri Alaleh was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +160.4% | +27.4% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +160.4% over three years. Forward estimates point to Revenue at +27.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.73B
Clover Health Investments, Corp.
NASDAQ:CLOV
$2.45B
Mesoblast Limited
NASDAQ:MESO
$1.79B
Inspire Medical Systems, Inc.
NYSE:INSP
$1.23B
Artivion, Inc.
NYSE:AORT
$975.72M
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
BGM Group Ltd.
NASDAQ:BGM
$75.23M
Who manages PRCT?
PROCEPT BioRobotics Corporation (PRCT) lists 10 active executives. The top listed executive is Alaleh Nouri, EVice President, Chief Legal Officer & Corporate Secretary.
Are PRCT insiders buying or selling?
Recent insider activity shows net selling of $44.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.